IDH1 and myelodysplastic syndrome: Olutasidenib (OLUTA; FT-2102), an allosteric non-competitive inhibitor of mutant IDH1 also demonstrated safety and efficacy with (N = 46) or without AZA (N = 32) in a phase 1/2 study of patients with IDH1-mutated AML or MDS [5,60].